Clinical Trials Browser

Terminated × Neoplasm Metastasis × Pemetrexed × Clear all

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04786964 2025-04-02

CONTERNO

Phase 3 Terminated

25 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02322281 2019-08-14

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Phase 3 Terminated

149 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02919462 2018-01-16

HighTySy

Phase 2 Terminated

2 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00280748 2017-06-23

NRR

Phase 2 Terminated

10 enrolled 14 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00864513 2015-12-08

Study of Pemetrexed for Second-Line Pancreas Cancer

Phase 2 Terminated

17 enrolled 9 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence

Clinical Trials

CANOPY-1

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

CONTERNO

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

HighTySy

NRR

Study of Pemetrexed for Second-Line Pancreas Cancer